What’s a late-stage IL-23 drug worth these days? We’re about to find out

6 years ago
R&D
Pharma

Part pro­ce­dure, part drug: Robert Ang joins Sid­dhartha Mukher­jee in pi­o­neer­ing a new type of cell en­gi­neer­ing

6 years ago
People
Startups

As­traZeneca, Mer­ck her­ald PhI­II prostate can­cer win for Lyn­parza — over­tak­ing Clo­vis, J&J in PARP race

6 years ago
R&D
Pharma

Rhythm Phar­ma­ceu­ti­cal­s' lead drug scores in piv­otal rare obe­si­ty tri­als

6 years ago
R&D

Faced with an­oth­er ethics scan­dal, No­var­tis CEO Vas Narasimhan as­sures an­a­lysts they tried to do 'the right thing'

6 years ago
Pharma
FDA+

Un­der a cloud of opi­oid law­suits, Mallinck­rodt sus­pends spe­cial­ty gener­ics spin­off

6 years ago
Deals

FDA en­dors­es No­vavax's piv­otal tri­al de­sign for flu vac­cine; Forty Sev­en bags fund­ing for myelodys­plas­tic syn­dromes ...

6 years ago
News Briefing

Biotech start­up joins quest to har­ness mi­cro­bio­me to un­teth­er re­liance on an­tibi­otics in wom­en's health

6 years ago
Startups

Gilead faces a hur­dle in its race for big, add-on OK for De­scovy as gener­ic Tru­va­da ri­vals loom

6 years ago
R&D
Pharma

Glax­o­SmithK­line drops out of Ebo­la vac­cine de­vel­op­ment as R&D shifts re­sources to fran­chise drugs

6 years ago
R&D

Sanofi, Re­gen­eron post back-to-back wins with new OK and a fresh round of pos­i­tive PhI­II da­ta for their block­buster ...

6 years ago
R&D

Ne­oleuk­in's quest to shake up the IL-2 space gets a boost via re­verse merg­er with Aquinox

6 years ago
Deals

In draft guid­ance, NICE fails to back Clo­vis's PARP in­hibitor Rubra­ca

6 years ago
Pharma
FDA+

Guardant blood test shows promise in pre­dict­ing im­munother­a­py re­sponse; As­traZeneca's di­a­betes drug wins EU la­bel ...

6 years ago
News Briefing

Take­da kicks up GPCR work with So­sei Hep­tares, dish­ing out $26M to get GI drug dis­cov­ery go­ing

6 years ago
Deals

Tiny Si­en­na is call­ing in Cowen as shares con­tin­ue to lan­guish long af­ter a se­vere tri­al set­back

6 years ago
R&D

Rac­ing af­ter the lead­ers, Eli Lil­ly's mi­graine drug clears an­oth­er piv­otal study

6 years ago
Pharma

Close to a decade af­ter Eli Lil­ly killed it, Jef­frey Blue­stone's 'break­through' drug is back and be­ing steered to the ...

6 years ago
R&D
FDA+

CMS pre­scribes pay­ment fix to re­sus­ci­tate US an­tibi­ot­ic in­dus­try

6 years ago
FDA+

Roche scores a no­table PhI­II suc­cess with Tecen­triq com­bo in blad­der can­cer, but is this an­oth­er case of too lit­tle ...

6 years ago
R&D
Pharma

Dai­ichi Sankyo scores land­mark FDA OK for rare tu­mor drug — al­beit with re­stric­tions

6 years ago
Pharma

Join­ing Chang and Bellde­grun, Rafael Ama­do takes a lead­ing R&D post in the next big cell ther­a­py rev­o­lu­tion

6 years ago
People
Cell/Gene Tx

Gly­coMimet­ics shares crash af­ter Pfiz­er team dis­miss­es their lead drug as a PhI­II fail­ure

6 years ago
R&D

David Apelian to steer TCR play at Pitt spin­out; Third Rock scoops Il­lu­mi­na ex­ec as CEO of can­cer de­tec­tion up­start

6 years ago
Peer Review
First page Previous page 925926927928929930931 Next page Last page
A service from the Financial Times